12 research outputs found
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
Objective Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications. Design We collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients-obtained using the Illumina immunochip-with their disease subphenotypes. Using logistic regression and Cox proportional hazards models, we identified genetic variants associated with binary and time-to-event PSC subphenotypes. Results We identified genetic variant rs853974 to be associated with liver transplant-free survival (p=6.07x10(-9)). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector cells, such as human and murine cholangiocytes and human hepatic stellate cells. Conclusion We present a large international PSC cohort, and report genetic loci associated with PSC disease progression. For liver transplant-free survival, we identified a genome-wide significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident effector cells. This warrants further assessments of the role of this potential key PSC modifier gene.Peer reviewe
General Approach To Determine Disulfide Connectivity in Cysteine-Rich Peptides by Sequential Alkylation on Solid Phase and Mass Spectrometry
Within the field of bioprospecting,
disulfide-rich peptides are
a promising group of compounds that has the potential to produce important
leads for new pharmaceuticals. The disulfide bridges stabilize the
tertiary structure of the peptides and often make them superior drug
candidates to linear peptides. However, determination of disulfide
connectivity in peptides with many disulfide bridges has proven to
be laborious and general methods are lacking. This study presents
a general approach for structure elucidation of disulfide-rich peptides.
The method features sequential reduction and alkylation of a peptide
on solid phase combined with sequencing of the fully alkylated peptide
by tandem mass spectrometry. Subsequently, the disulfide connectivity
is assigned on the basis of the determined alkylation pattern. The
presented method is especially suitable for peptides that are prone
to disulfide scrambling or are unstable in solution with partly reduced
bridges. Additionally, the use of small amounts of peptide in the
lowest nmol range makes the method ideal for structure elucidation
of unknown peptides from the bioprospecting process. This study successfully
demonstrates the new method for seven different peptides with two
to four disulfide bridges. Two peptides with previous contradicting
publications, μ-conotoxin KIIA and hepcidin-25, are included,
and their disulfide connectivity is confirmed in accordance with the
latest published results
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
Abstract Oncolytic peptides represent a novel, promising cancer treatment strategy with activity in a broad spectrum of cancer entities, including colorectal cancer (CRC). Cancer cells are killed by immunogenic cell death, causing long-lasting anticancer immune responses, a feature of particular interest in non-immunogenic CRC. Oncolytic peptides DTT-205 and DTT-304 were administered by intratumoral injection in subcutaneous tumors established from murine CRC cell lines CT26 and MC38, and complete regression was obtained in the majority of animals. When cured animals were rechallenged by splenic injection of tumor cells, 1/23 animals developed liver metastases, compared to 19/22 naïve animals. Treatment with both peptides was well tolerated, but monitoring post-injection hemodynamic parameters in rats, less extensive changes were observed with DTT-205 than DTT-304, favoring DTT-205 for future drug development. DTT-205 was subsequently shown to have strong in vitro activity in a panel of 33 cancer cell lines. In conclusion, both peptides exerted a strong inhibitory effect in two immunocompetent CRC models and induced a systemic effect preventing development of liver metastases upon splenic rechallenge. If a similar effect could be obtained in humans, these drugs would be of particular interest for combinatory treatment with immune checkpoint inhibitors in metastatic CRC
Iterative Design and in Vivo Evaluation of an Oncolytic Antilymphoma Peptide
Oncolytic
peptides represent a promising new strategy within the
field of cancer immunotherapy. Here we describe the systematic design
and evaluation of short antilymphoma peptides within this paradigm.
The peptides were tested in vitro and in vivo to identify a lead compound
for further evaluation as novel oncolytic immunotherapeutic. In vitro
tests revealed peptides with high activity against several lymphoma
types and low cytotoxicity toward normal cells. Treated lymphoma cells
exhibited a reduced mitochondrial membrane potential that resulted
in an irreversible disintegration of their plasma membranes. No caspase
activation or ultrastructural features of apoptotic cell death were
observed. One of these peptides, <b>11</b>, was shown to induce
complete tumor regression and protective immunity following intralesional
treatment of murine A20 B-lymphomas. Due to its selectivity for lymphoma
cells and its ability to induce tumor-specific immune responses, <b>11</b> has the potential to be used in intralesional treatment
of accessible lymphoma tumors
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
Objective Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications. Design We collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients-obtained using the Illumina immunochip-with their disease subphenotypes. Using logistic regression and Cox proportional hazards models, we identified genetic variants associated with binary and time-to-event PSC subphenotypes. Results We identified genetic variant rs853974 to be associated with liver transplant-free survival (p=6.07x10(-9)). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector cells, such as human and murine cholangiocytes and human hepatic stellate cells. Conclusion We present a large international PSC cohort, and report genetic loci associated with PSC disease progression. For liver transplant-free survival, we identified a genome-wide significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident effector cells. This warrants further assessments of the role of this potential key PSC modifier gene
Recommended from our members
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.
Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown etiology leading to fibrotic destruction of the bile ducts and ultimately to the need for liver transplantation. We compared 3,789 PSC cases of European ancestry to 25,079 population controls across 130,422 SNPs genotyped using the Immunochip. We identified 12 genome-wide significant associations outside the human leukocyte antigen (HLA) complex, 9 of which were new, increasing the number of known PSC risk loci to 16. Despite comorbidity with inflammatory bowel disease (IBD) in 72% of the cases, 6 of the 12 loci showed significantly stronger association with PSC than with IBD, suggesting overlapping yet distinct genetic architectures for these two diseases. We incorporated association statistics from 7 diseases clinically occurring with PSC in the analysis and found suggestive evidence for 33 additional pleiotropic PSC risk loci. Together with network analyses, these findings add to the genetic risk map of PSC and expand on the relationship between PSC and other immune-mediated diseases